| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3 ☆
|
Goetz, M.P.
|
|
|
35 |
8 |
p. 718-727
|
article
|
| 2 |
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
|
Hamilton, E.
|
|
|
35 |
8 |
p. 707-717
|
article
|
| 3 |
Corrigendum to ‘Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma’
|
Sharon, C.E.
|
|
|
35 |
8 |
p. 756
|
article
|
| 4 |
Editorial Board
|
|
|
|
35 |
8 |
p. iii
|
article
|
| 5 |
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma
|
Menzies, A.M.
|
|
|
35 |
8 |
p. 739-746
|
article
|
| 6 |
Immune Checkpoint Inhibitors in Endometrial Cancer: A Cinderella Story
|
Colombo, N.
|
|
|
35 |
8 |
p. 686-688
|
article
|
| 7 |
Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding “Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3” by M. P. Goetz et al.
|
Sherry, A.D.
|
|
|
35 |
8 |
p. 747-748
|
article
|
| 8 |
Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors
|
Sánchez-Bayona, Rodrigo
|
|
|
35 |
8 |
p. 689-691
|
article
|
| 9 |
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial
|
Powell, M.A.
|
|
|
35 |
8 |
p. 728-738
|
article
|
| 10 |
Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: “Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up” by Huguet et al.
|
Huguet, F.
|
|
|
35 |
8 |
p. 749-750
|
article
|
| 11 |
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Powles, T.
|
|
|
35 |
8 |
p. 692-706
|
article
|
| 12 |
Reply to ‘Letter to the Editor regarding “Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial [NCT00541047]”, by C. C. Parker et al.’
|
Parker, C.C.
|
|
|
35 |
8 |
p. 752-753
|
article
|
| 13 |
Reply to the Letter to the Editor ‘Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten’ (in regard to “Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up”) by Huguet et al.
|
Conroy, T.
|
|
|
35 |
8 |
p. 750-751
|
article
|
| 14 |
Re: “Timing of radiotherapy (RT) after radical prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial [NCT00541047]”, by C. C. Parker et al. Ann Oncol. 2024 Apr 5:S0923-7534(24)00105-4
|
Mazzone, E.
|
|
|
35 |
8 |
p. 751-752
|
article
|
| 15 |
Table of Contents
|
|
|
|
35 |
8 |
p. i-ii
|
article
|
| 16 |
The new oral SERDs in endocrine-resistant breast cancer: who will benefit the most?
|
Migliaccio, I.
|
|
|
35 |
8 |
p. 683-685
|
article
|
| 17 |
To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: Final overall survival results of MONARCH 3’ by M. P. Goetz et al.
|
Orlandi, A.
|
|
|
35 |
8 |
p. 748-749
|
article
|
| 18 |
VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study
|
Metcalf, R.
|
|
|
35 |
8 |
p. 754-755
|
article
|
Journal description